2023
18F-FP-DTBZ PET/CT detectable associations between monoaminergic depletion in the putamen with rigidity and the pallidus with tremor in Parkinson's disease
Huang A, Liu S, Barret O, Qiao H, Tamagnan G, Liu X, Fan C, Li Z, Lu J, Chan P, Xu E. 18F-FP-DTBZ PET/CT detectable associations between monoaminergic depletion in the putamen with rigidity and the pallidus with tremor in Parkinson's disease. Parkinsonism & Related Disorders 2023, 120: 105979. PMID: 38241952, DOI: 10.1016/j.parkreldis.2023.105979.Peer-Reviewed Original ResearchPostural instability gait difficultyMotor subtypesParkinson's diseaseStandardized uptake value ratioDifferent motor subtypesStriatal dopaminergic depletionParkinsonian motor symptomsUptake value ratioPET/CTDopaminergic disruptionMonoaminergic depletionMonoaminergic changesDopaminergic depletionMotor symptomsPIGD scoresDorsal putamenPD subtypesVentral putamenPD pathogenesisPrognosis evaluationPatientsDominant subtypeMethods SixtyAccurate diagnosisDifferent subtypes
2011
P2‐035: Preliminary evaluation of the amyloid PET Radioligand [18F]MK‐3328 in Alzheimer's Disease patients
Sanabria‐Bohorquez S, Hostetler E, Van Laere K, Koole M, Bormans G, Serdons K, de Hoon J, Vandenberghe R, Versijpt J, De Lepeleire I, Reynders T, Tamagnan G, Marek K, Seibyl J, Jennings D, Barret O, Koren A, Rosen L, Hargreaves R, Evelhoch J, Sur C, Forman M. P2‐035: Preliminary evaluation of the amyloid PET Radioligand [18F]MK‐3328 in Alzheimer's Disease patients. Alzheimer's & Dementia 2011, 7: s319-s319. DOI: 10.1016/j.jalz.2011.05.925.Peer-Reviewed Original Research
2008
IC‐P3‐215: Automated image processing algorithms for evaluating novel 123‐Iodine‐labeled beta‐amyloid imaging agents MNI‐187 and MNI‐308 in Alzheimer's patients
Seibyl J, Marek K, Jennings D, Tamagnan G, Zubal G. IC‐P3‐215: Automated image processing algorithms for evaluating novel 123‐Iodine‐labeled beta‐amyloid imaging agents MNI‐187 and MNI‐308 in Alzheimer's patients. Alzheimer's & Dementia 2008, 4: t91-t92. DOI: 10.1016/j.jalz.2008.05.160.Peer-Reviewed Original ResearchAlzheimer patientsPatientsP4‐346: Safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimer's disease
Siemers E, Friedrich S, Dean R, Sethuraman G, DeMattos R, Jennings D, Tamagnan G, Marek K, Seibyl J. P4‐346: Safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimer's disease. Alzheimer's & Dementia 2008, 4: t774-t774. DOI: 10.1016/j.jalz.2008.05.2416.Peer-Reviewed Original Research